These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 25544240)

  • 1. A cisplatin‑incorporated liposome that targets the epidermal growth factor receptor enhances radiotherapeutic efficacy without nephrotoxicity.
    Jung J; Jeong SY; Park SS; Shin SH; Ju EJ; Choi J; Park J; Lee JH; Kim I; Suh YA; Hwang JJ; Kuroda S; Lee JS; Song SY; Choi EK
    Int J Oncol; 2015 Mar; 46(3):1268-74. PubMed ID: 25544240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cisplatin-alginate conjugate liposomes for targeted delivery to EGFR-positive ovarian cancer cells.
    Wang Y; Zhou J; Qiu L; Wang X; Chen L; Liu T; Di W
    Biomaterials; 2014 May; 35(14):4297-309. PubMed ID: 24565522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination therapy with VEGFR2 and EGFR siRNA enhances the antitumor effect of cisplatin in non-small cell lung cancer xenografts.
    Chen S; Liu X; Gong W; Yang H; Luo D; Zuo X; Li W; Wu P; Liu L; Xu Q; Ji A
    Oncol Rep; 2013 Jan; 29(1):260-8. PubMed ID: 23117577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer.
    Li B; Ren S; Li X; Wang Y; Garfield D; Zhou S; Chen X; Su C; Chen M; Kuang P; Gao G; He Y; Fan L; Fei K; Zhou C; Schmit-Bindert G
    Lung Cancer; 2014 Feb; 83(2):146-53. PubMed ID: 24331411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bevacizumab radiosensitizes non-small cell lung cancer xenografts by inhibiting DNA double-strand break repair in endothelial cells.
    Gao H; Xue J; Zhou L; Lan J; He J; Na F; Yang L; Deng L; Lu Y
    Cancer Lett; 2015 Aug; 365(1):79-88. PubMed ID: 25982206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymeric nanoparticles containing taxanes enhance chemoradiotherapeutic efficacy in non-small cell lung cancer.
    Jung J; Park SJ; Chung HK; Kang HW; Lee SW; Seo MH; Park HJ; Song SY; Jeong SY; Choi EK
    Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):e77-83. PubMed ID: 22795728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor growth inhibition with cetuximab and chemotherapy in non-small cell lung cancer xenografts expressing wild-type and mutated epidermal growth factor receptor.
    Steiner P; Joynes C; Bassi R; Wang S; Tonra JR; Hadari YR; Hicklin DJ
    Clin Cancer Res; 2007 Mar; 13(5):1540-51. PubMed ID: 17332300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects.
    Stabile LP; Lyker JS; Gubish CT; Zhang W; Grandis JR; Siegfried JM
    Cancer Res; 2005 Feb; 65(4):1459-70. PubMed ID: 15735034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cationic liposome-mediated nitric oxide synthase gene therapy enhances the antitumor effects of cisplatin in lung cancer.
    Ye S; Yang W; Wang Y; Ou W; Ma Q; Yu C; Ren J; Zhong G; Shi H; Yuan Z; Su X; Zhu W
    Int J Mol Med; 2013 Jan; 31(1):33-42. PubMed ID: 23128378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition.
    Thomson S; Buck E; Petti F; Griffin G; Brown E; Ramnarine N; Iwata KK; Gibson N; Haley JD
    Cancer Res; 2005 Oct; 65(20):9455-62. PubMed ID: 16230409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erlotinib antitumor activity in non-small cell lung cancer models is independent of HER1 and HER2 overexpression.
    Friess T; Scheuer W; Hasmann M
    Anticancer Res; 2006; 26(5A):3505-12. PubMed ID: 17094474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. S100A2 promoter-driven conditionally replicative adenovirus targets non-small-cell lung carcinoma.
    Lee K; Yun ST; Yun CO; Ahn BY; Jo EC
    Gene Ther; 2012 Oct; 19(10):967-77. PubMed ID: 22033466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
    Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
    Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PLK1 and EGFR targeted nanoparticle as a radiation sensitizer for non-small cell lung cancer.
    Reda M; Ngamcherdtrakul W; Gu S; Bejan DS; Siriwon N; Gray JW; Yantasee W
    Cancer Lett; 2019 Dec; 467():9-18. PubMed ID: 31563561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo.
    Xie M; He CS; Wei SH; Zhang L
    Eur J Cancer; 2013 Nov; 49(16):3559-72. PubMed ID: 23916913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidermal growth factor receptor mutation is associated with longer local control after definitive chemoradiotherapy in patients with stage III nonsquamous non-small-cell lung cancer.
    Yagishita S; Horinouchi H; Katsui Taniyama T; Nakamichi S; Kitazono S; Mizugaki H; Kanda S; Fujiwara Y; Nokihara H; Yamamoto N; Sumi M; Shiraishi K; Kohno T; Furuta K; Tsuta K; Tamura T
    Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):140-8. PubMed ID: 25442336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva).
    Chinnaiyan P; Huang S; Vallabhaneni G; Armstrong E; Varambally S; Tomlins SA; Chinnaiyan AM; Harari PM
    Cancer Res; 2005 Apr; 65(8):3328-35. PubMed ID: 15833866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells.
    Martinelli E; Troiani T; Morgillo F; Rodolico G; Vitagliano D; Morelli MP; Tuccillo C; Vecchione L; Capasso A; Orditura M; De Vita F; Eckhardt SG; Santoro M; Berrino L; Ciardiello F
    Clin Cancer Res; 2010 Oct; 16(20):4990-5001. PubMed ID: 20810384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical evaluation of cisplatin-incorporated bio-nanocapsules as chemo-radiotherapy for human hepatocellular carcinoma.
    Shin SH; Park SS; Lee KJ; Ju EJ; Park J; Ko EJ; Jung J; Kuroda S; Hong SM; Hwang JJ; Lee JS; Song SY; Jeong SY; Choi EK
    Oncol Rep; 2017 Oct; 38(4):2259-2266. PubMed ID: 28849069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa).
    Bianco C; Tortora G; Bianco R; Caputo R; Veneziani BM; Caputo R; Damiano V; Troiani T; Fontanini G; Raben D; Pepe S; Bianco AR; Ciardiello F
    Clin Cancer Res; 2002 Oct; 8(10):3250-8. PubMed ID: 12374696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.